Top

Published in:

Open Access 01-12-2022 | Study protocol

The haemostatic effect of deep-frozen platelets versus room temperature-stored platelets in the treatment of surgical bleeding: MAFOD—study protocol for a randomized controlled non-inferiority trial

Authors: Tim W. H. Rijnhout, Femke Noorman, Robert A. van der Horst, Edward C. T. H. Tan, Victor V. A. Viersen, Oscar J. F. van Waes, Leo M. G. van de Watering, B. L. S. Borger van der Burg, Jaap J. Zwaginga, Michael H. J. Verhofstad, Rigo Hoencamp

Published in: Trials | Issue 1/2022

Abstract

Background

The Netherlands Armed Forces have been successfully using deep-frozen (− 80 °C) thrombocyte concentrate (DTC) for the treatment of (massive) bleeding trauma patients in austere environments since 2001. However, high-quality evidence for the effectiveness and safety of DTCs is currently lacking. Therefore, the MAssive transfusion of Frozen bloOD (MAFOD) trial is designed to compare the haemostatic effect of DTCs versus room temperature-stored platelets (RSP) in the treatment of surgical bleeding.

Methods

The MAFOD trial is a single-blinded, randomized controlled non-inferiority trial and will be conducted in three level 1 trauma centres in The Netherlands. Patients 12 years or older, alive at hospital presentation, requiring a massive transfusion including platelets and with signed (deferred) consent will be included. The primary outcome is the percentage of patients that have achieved haemostasis within 6 h and show signs of life. Haemostasis is defined as the time in minutes from arrival to the time of the last blood component transfusion (plasma/platelets or red blood cells), followed by a 2-h transfusion-free period. This is the first randomized controlled study investigating DTCs in trauma and vascular surgical bleeding.

Discussion

The hypothesis is that the percentage of patients that will achieve haemostasis in the DTC group is at least equal to the RSP group (85%). With a power of 80%, a significance level of 5% and a non-inferiority limit of 15%, a total of 71 patients in each arm are required, thus resulting in a total of 158 patients, including a 10% refusal rate. The data collected during the study could help improve the use of platelets during resuscitation management. If proven non-inferior in civilian settings, frozen platelets may be used in the future to optimize logistics and improve platelet availability in rural or remote areas for the treatment of (massive) bleeding trauma patients in civilian settings.

Trial registration

ClinicalTrials.gov NCT05502809. Registered on 16 August 2022.

Available only for authorised users

Eastridge BJ, Holcomb JB, Shackelford S. Outcomes of traumatic hemorrhagic shock and the epidemiology of preventable death from injury. Transfusion. 2019;59(S2):1423–8.CrossRef

Eastridge BJ, Mabry RL, Seguin P, Cantrell J, Tops T, Uribe P, et al. Death on the battlefield (2001-2011): implications for the future of combat casualty care. J Trauma Acute Care Surg. 2012;73(6 Suppl 5):S431–7.CrossRef

Geeraedts LM Jr, Pothof LA, Caldwell E, de Lange-de Klerk ES, D’Amours SK. Prehospital fluid resuscitation in hypotensive trauma patients: do we need a tailored approach? Injury. 2015;46(1):4–9.CrossRef

Holcomb JB, Tilley BC, Baraniuk S, Fox EE, Wade CE, Podbielski JM, et al. Transfusion of plasma, platelets, and red blood cells in a 1:1:1 vs a 1:1:2 ratio and mortality in patients with severe trauma: the PROPPR randomized clinical trial. Jama. 2015;313(5):471–82.CrossRef

Lelkens CC, Koning JG, de Kort B, Floot IB, Noorman F. Experiences with frozen blood products in the Netherlands military. Transfus Apher Sci. 2006;34(3):289–98.CrossRef

Noorman F, Rijnhout TWH, Zoodsma M, Hoencamp R. 80 °C deep frozen erythrocytes during military operations. The Dutch frozen concept. Transfus Apher Sci. 2020;59(3):102789.CrossRef

Noorman F, van Dongen TT, Plat MJ, Badloe JF, Hess JR, Hoencamp R. Transfusion: -80 degrees C frozen blood products are safe and effective in military casualty care. PLoS One. 2016;11(12):e0168401.CrossRef

Holley A, Marks DC, Johnson L, Reade MC, Badloe JF, Noorman F. Frozen blood products: clinically effective and potentially ideal for remote Australia. Anaesth Intensive Care. 2013;41(1):10–9.CrossRef

Khuri SF, Healey N, MacGregor H, Barnard MR, Szymanski IO, Birjiniuk V, et al. Comparison of the effects of transfusions of cryopreserved and liquid-preserved platelets on hemostasis and blood loss after cardiopulmonary bypass. J Thorac Cardiovasc Surg. 1999;117(1):172–83 discussion 83-4.CrossRef

10.

Slichter SJ, Dumont LJ, Cancelas JA, Jones M, Gernsheimer TB, Szczepiorkowski ZM, et al. Safety and efficacy of cryopreserved platelets in bleeding patients with thrombocytopenia. Transfusion. 2018;58(9):2129–38.CrossRef

11.

Kleinveld DJB, Juffermans NP, Noorman F. The use of frozen platelets for the treatment of bleeding. In: Vincent J-L, editor. Annual Update in Intensive Care and Emergency Medicine 2020. Cham: Springer International Publishing; 2020. p. 317–29.CrossRef

12.

Kleinveld DJB, Sloos PH, Noorman F, Maas MAW, Kers J, Rijnhout TWH, et al. The use of cryopreserved platelets in a trauma-induced hemorrhage model. Transfusion. 2020;60(9):2079–89.PubMedPubMedCentral

13.

Baksaas-Aasen K, Gall LS, Stensballe J, Juffermans NP, Curry N, Maegele M, et al. Viscoelastic haemostatic assay augmented protocols for major trauma haemorrhage (ITACTIC): a randomized, controlled trial. Intensive Care Med. 2021;47(1):49–59.CrossRef

14.

McGuinness S, Charlewood R, Gilder E, Parke R, Hayes K, Morley S, et al. A pilot randomized clinical trial of cryopreserved versus liquid-stored platelet transfusion for bleeding in cardiac surgery: the cryopreserved versus liquid platelet-New Zealand pilot trial. Vox Sang. 2022;117(3):337–45.CrossRef

Title: The haemostatic effect of deep-frozen platelets versus room temperature-stored platelets in the treatment of surgical bleeding: MAFOD—study protocol for a randomized controlled non-inferiority trial
Authors: Tim W. H. Rijnhout
Femke Noorman
Robert A. van der Horst
Edward C. T. H. Tan
Victor V. A. Viersen
Oscar J. F. van Waes
Leo M. G. van de Watering
B. L. S. Borger van der Burg
Jaap J. Zwaginga
Michael H. J. Verhofstad
Rigo Hoencamp
Publication date: 01-12-2022
Publisher: BioMed Central
Published in: Trials / Issue 1/2022
Electronic ISSN: 1745-6215
DOI: https://doi.org/10.1186/s13063-022-06739-2

Keynote webinar | Spotlight on medication adherence

Springer Medicine

The haemostatic effect of deep-frozen platelets versus room temperature-stored platelets in the treatment of surgical bleeding: MAFOD—study protocol for a randomized controlled non-inferiority trial

Abstract

Background

Methods

Discussion

Trial registration

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Discussion

Trial registration

Please log in to get access to this content

Other articles of this Issue 1/2022

A good use of time? Providing evidence for how effort is invested in primary and secondary outcome data collection in trials

Effects of photobiomodulation on re-epithelialization of burn wound: protocol for a randomized controlled trial

Sharing individual participant data: through a systematic reviewer lens

Establishing a Core Domain Set for early-phase clinical trials of electrical stimulation interventions for tinnitus in adults: protocol for an online Delphi study

Safety and effectiveness of delivering mass drug administration for helminths through the seasonal malaria chemoprevention platform among Senegalese children: study protocol for a randomised controlled trial

Efficacy and safety of ivermectin in the treatment of mild to moderate COVID-19 infection: a randomized, double-blind, placebo-controlled trial